Patients with cancer who received prophylactic intravenous (IV) magnesium before starting cisplatin had a lower risk for cisplatin-associated acute kidney injury (AKI) than those who did not receive ...

Patients with cancer who received IV magnesium on the day of cisplatin administration had significant 27% lower odds of cisplatin-associated AKI compared with those who did not receive IV magnesium.

The odds of cisplatin-induced acute kidney injury decreased with prophylactic administration of intravenous magnesium. Infusing prophylactic magnesium before initiating intravenous cisplatin for ...

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women's Hospital are the first and senior authors, respectively, of a paper published in ...

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women’s Hospital are the first and senior authors, respectively, of a paper published in ...

Using patient data from six major U.S. cancer centers, Brigham researchers and collaborators developed a risk prediction model for moderate-to-severe kidney injury after receiving the chemotherapy ...

Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2013 ASCO Annual ...

Certain patient characteristics may put them at an increased risk for chemotherapy-related kidney injury, recent research found. Researchers potentially found a way to determine which patients are ...